Grants and Contributions:
Title:
EUREKA Project 2020-15143 RESOLCOVID – COVID Related Inflammation - Tracking of SPMs
Agreement Number:
962517
Agreement Value:
$259,520.00
Agreement Date:
Dec 28, 2020 - Dec 31, 2021
Description:
EUREKA project 15143 RESOLCOVID with SOLUTEX GC SL (Spain). Nutrasource and Solutex are partnering to research determine which SPMs are the most highly correlated with COVID-19 disease outcome and severity. The most important SPMs will then be developed into a diagnostic device.
Organization:
National Research Council Canada
Expected Results:
Eureka promotes and supports market-oriented international R&D&I project generation, and facilitates access to financing for companies involved in its projects. EUREKA’s strength lies in its well-established international network, connecting 41 full member countries from Europe and 4 associated member countries.
Location:
Guelph, Ontario, CA N1G 0B4
Reference Number:
172-2020-2021-Q4-962517
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
865125264
Recipient Type:
For-profit organization
Recipient's Operating Name:
NDI
Recipient's Legal Name:
Nutrasource Pharmaceutical and Nutraceutical Services Inc.
Federal Riding Name:
Guelph
Federal Riding Number:
35032
Program:
Eureka/Eurostar
Program Purpose:
Eureka promotes and supports market-oriented international R&D&I project generation, and facilitates access to financing for companies involved in its projects. EUREKA’s strength lies in its well-established international network, connecting 41 full member countries from Europe and 4 associated member countries.
Coverage:
EUREKA is a leading facilitator of innovation, providing a proven platform for international R&D&I cooperation.
NAICS Code:
541710